Literature DB >> 24337740

Cutting edge: DNAX accessory molecule 1-deficient CD8+ T cells display immunological synapse defects that impair antitumor immunity.

Kelly M Ramsbottom1, Edwin D Hawkins, Raz Shimoni, Mairi McGrath, Christopher J Chan, Sarah M Russell, Mark J Smyth, Jane Oliaro.   

Abstract

DNAX accessory molecule 1 (DNAM-1) is expressed on all CD8(+) T cells and promotes their activation and effector function. DNAM-1 interacts with LFA-1, a critical molecule for immunological synapse formation between T cells and APCs, and for cytotoxic killing of target cells. Mice that lack DNAM-1 display abnormal T cell responses and antitumor activity; however, the mechanism involved is unclear. In this article, we show that DNAM-1 deficiency results in reduced proliferation of CD8(+) T cells after Ag presentation and impaired cytotoxic activity. We also demonstrate that DNAM-1-deficient T cells show reduced conjugations with tumor cells and decreased recruitment of both LFA-1 and lipid rafts to the immunological synapse, which correlates with reduced tumor cell killing in vitro. This synapse defect may explain why DNAM-1-deficient mice cannot clear tumors in vivo, and highlights the importance of DNAM-1 and the immunological synapse in T cell-mediated antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337740     DOI: 10.4049/jimmunol.1302197

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors:  Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2020-06-26       Impact factor: 12.531

2.  Lethal giant larvae-1 deficiency enhances the CD8(+) effector T-cell response to antigen challenge in vivo.

Authors:  Kelly M Ramsbottom; Faruk Sacirbegovic; Edwin D Hawkins; Axel Kallies; Gabrielle T Belz; Vanessa Van Ham; Nicole M Haynes; Michael J Durrant; Patrick O Humbert; Sarah M Russell; Jane Oliaro
Journal:  Immunol Cell Biol       Date:  2015-09-22       Impact factor: 5.126

Review 3.  Balancing natural killer cell activation through paired receptors.

Authors:  Ludovic Martinet; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2015-03-06       Impact factor: 53.106

Review 4.  Targeting novel inhibitory receptors in cancer immunotherapy.

Authors:  Quan-Quan Ding; Joe-Marc Chauvin; Hassane M Zarour
Journal:  Semin Immunol       Date:  2020-12-04       Impact factor: 11.130

5.  Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Authors:  Camille Guillerey; Lucas Ferrari de Andrade; Slavica Vuckovic; Kim Miles; Shin Foong Ngiow; Michelle C R Yong; Michele W L Teng; Marco Colonna; David S Ritchie; Marta Chesi; Martha Chesi; P Leif Bergsagel; Geoffrey R Hill; Mark J Smyth; Ludovic Martinet
Journal:  J Clin Invest       Date:  2015-04-20       Impact factor: 14.808

6.  Cd226-/- natural killer cells fail to establish stable contacts with cancer cells and show impaired control of tumor metastasis in vivo.

Authors:  Ji Sung Kim; Bo Ram Shin; Hong Kyung Lee; Jae Hee Lee; Ki Hun Kim; Jeong Eun Choi; A Young Ji; Jin Tae Hong; Youngsoo Kim; Sang-Bae Han
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

7.  Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1.

Authors:  Felix A Deuss; Gabrielle M Watson; Katharine J Goodall; Isobel Leece; Sayantani Chatterjee; Zhihui Fu; Morten Thaysen-Andersen; Daniel M Andrews; Jamie Rossjohn; Richard Berry
Journal:  J Biol Chem       Date:  2019-06-28       Impact factor: 5.157

8.  Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.

Authors:  María V Martínez-Sánchez; Adela Periago; Isabel Legaz; Lourdes Gimeno; Anna Mrowiec; Natividad R Montes-Barqueros; José A Campillo; José M Bolarin; María V Bernardo; María R López-Álvarez; Consuelo González; María C García-Garay; Manuel Muro; Valentin Cabañas-Perianes; Jose L Fuster; Ana M García-Alonso; José M Moraleda; María R Álvarez-Lopez; Alfredo Minguela
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

Review 9.  Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity.

Authors:  Peng Xiong; Hai-Wei Sang; Min Zhu
Journal:  Immunology       Date:  2015-09-28       Impact factor: 7.397

10.  CD226 opposes TIGIT to disrupt Tregs in melanoma.

Authors:  Julien Fourcade; Zhaojun Sun; Joe-Marc Chauvin; Mignane Ka; Diwakar Davar; Ornella Pagliano; Hong Wang; Sofiane Saada; Carmine Menna; Rada Amin; Cindy Sander; John M Kirkwood; Alan J Korman; Hassane M Zarour
Journal:  JCI Insight       Date:  2018-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.